Drugs / HDV-Lispro
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06238778 | Jan 2024 → Oct 2025 overdue | type 1 diabetes mellitus | Diasome Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDV-Lispro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06238778 ↗ |
| Known as | Hepatocyte-Directed Vesicles-insulin lispro | “Hepatocyte-Directed Vesicles-insulin lispro (HDV-L) versus lispro alone (LIS) used in combination with insulin degludec.” NCT06238778 ↗ |